These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23873823)

  • 1. Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.
    Beguin Y; Maertens J; De Prijck B; Schots R; Seidel L; Bonnet C; Hafraoui K; Willems E; Vanstraelen G; Servais S; Jaspers A; Fillet G; Baron F
    Am J Hematol; 2013 Dec; 88(12):990-6. PubMed ID: 23873823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
    Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
    Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
    Jaspers A; Baron F; Maertens J; De Prijck B; Schots R; Bonnet C; Hafraoui K; Willems É; Servais S; Fillet G; Beguin Y
    Am J Hematol; 2015 Jul; 90(7):E133-4. PubMed ID: 25802012
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
    Baron F; Frère P; Fillet G; Beguin Y
    Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Bastit L; Vandebroek A; Altintas S; Gaede B; Pintér T; Suto TS; Mossman TW; Smith KE; Vansteenkiste JF
    J Clin Oncol; 2008 Apr; 26(10):1611-8. PubMed ID: 18375890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of IV iron compared to oral iron for increment of haemoglobin level in anemic chronic kidney disease patients on erythropoietin therapy.
    Adhikary L; Acharya S
    JNMA J Nepal Med Assoc; 2011; 51(183):133-6. PubMed ID: 22922860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
    Krafft A; Breymann C
    J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
    Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
    Bolger AP; Bartlett FR; Penston HS; O'Leary J; Pollock N; Kaprielian R; Chapman CM
    J Am Coll Cardiol; 2006 Sep; 48(6):1225-7. PubMed ID: 16979010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
    J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Smith RE; Aapro MS; Ludwig H; Pintér T; Smakal M; Ciuleanu TE; Chen L; Lillie T; Glaspy JA
    J Clin Oncol; 2008 Mar; 26(7):1040-50. PubMed ID: 18227526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.